Jun 28, 2019 8:00am EDT Nexera Pharmaceuticals Schedules Fourth Quarter and Fiscal 2019 Conference Call
Jun 25, 2019 8:00am EDT Nexera Appoints Accomplished Global Pharmaceutical Industry Executive Adele M. Gulfo to its Board of Directors
May 07, 2019 12:43pm EDT Nexera Pharmaceuticals Launches New Metoject® Subcutaneous 15mg Dosage for the Treatment of Rheumatoid Arthritis, Psoriasis and Psoriatic Arthritis in Canada
Mar 06, 2019 7:50am EST Nexera Granted Authorization by Health Canada to Distribute Treosulfan in Canada
Feb 25, 2019 4:05pm EST Nexera Pharmaceuticals Announces 512% Increase in Revenue to $14.4 Million for the Third Quarter of Fiscal 2019
Feb 12, 2019 8:00am EST Nexera Lists October 2018 Unsecured Convertible Debentures on the TSX Venture Exchange
